Category Archives: Business and Investments

Latest From Business and Investments

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Call for Nominations: BIO International Convention’s Buzz of BIO Contest

Buzz of BIO

The BIO International Convention is all about raising your profile. Make connections, get your story heard, move business forward. One of the more creative and fun ways to accomplish these goals is the Buzz of BIO contest. This is an online voting contest for the industry to cast their pick for this year’s most creative biotech company. Nominate Your Company The contest is open to R&D-intensive companies looking to develop strategic partnerships within the industry. Answer Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

A Bright Future for Orphan Disease Indications

Chart

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals).   Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , ,

BIO One-on-One Partnering Opens for BIO International Convention

Partnering

The 2013 BIO International Convention and BIO Business Forum is kicking in to full gear! And today is a big day! The BIO One-on-One Partnering System™ for the event has officially launched! This means that login credentials are being sent to registered participants, who can access the site to set up their profiles and send and accept meeting requests. We had a stellar year last year, where records were legitimately broken. So here’s to breaking new Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The IPO Road Less Traveled: Form 10

When investors talk about alternate exits for private companies beyond the traditional IPO they are usually referring to reverse mergers, if not outright acquisitions. However, another route is gaining some traction with sophisticated biotech investors – the so-called Form-10 pathway. Although it can be used in combination with reverse mergers, recent SEC rules applied to reverse mergers have shifted interest towards a more direct Form-10 approach to public markets. At last week’s BIO CEO & Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post